3-month gap between Oxford’s COVID-19 doses more effective: Lancet
Category: #healthcare  By Mateen Dalal  Date: 2021-02-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

3-month gap between Oxford’s COVID-19 doses more effective: Lancet

The popular weekly general medical journal, ‘The Lancet’, has revealed that the COVID-19 vaccine developed by The University of Oxford and AstraZeneca PLC, is more effective with a three-month gap between the first and second dose rather than the six-week gap recommended by the U.S. CDC (Centers for Disease Control and Prevention).

If sources are to be believed, the study published in the journal has estimated that the first dose of the vaccine can offer up to 76% protection for three months. The journal also suggests that the interval between the doses can safely be extended to three months by the government, for immunizing more people in the gap period.

The lead author of the study, Andrew Pollard was reported saying that policymakers must propose the best dosage delivery procedures to achieve utmost public health benefit as vaccine supply is expected to be limited initially. The second dose is highly recommended, in the long term, as should facilitate a long-lasting immune response, he added.

Reportedly, the team of researchers combined the data of around 17,178 adult participants from randomized controlled clinical trials conducted in South Africa, Brazil, and the United Kingdom. Among these, 8,581 participants were inoculated with a control vaccine (saline placebo) while the remaining 8,597 were given two standard doses of the Oxford vaccine.

The vaccine, administered with an interval of 12 or more weeks, reflected 81% protection, while individuals who were given doses with less than six weeks of interval recorded 55% protection, confirmed sources. The study also found that the level of antibodies against the SARS-CoV-2 spike protein remained the same throughout three months.

On the contrary, the authors mentioned that the effects of the protective shield offered by a single dose of the vaccine are questionable for a period of more than three months as the study was conducted for up to three months.

Covishield is currently being manufactured in India by Pune-headquartered pharmaceutical and biotechnology company Serum Institute of India Pvt. Ltd.

Source credits –

https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-update-3-month-gap-between-doses-could-make-oxford-astrazenecas-covishield-more-effective-says-lancet/2198426/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

FDA approves mix-and-match boosters for Pfizer, Moderna, and J&J jabs
FDA approves mix-and-match boosters for Pfizer, Moderna, and J&J jabs
By Mateen Dalal

The FDA (Food and Drug Administration) has reportedly approved booster shots for Johnson & Johns...

Tesla Q4 results uncertain over China factory, supply chain concerns
Tesla Q4 results uncertain over China factory, supply chain concerns
By Mateen Dalal

EV leader Tesla has fared better than others amid the global chip shortage, however, supply-chain is...

Melbourne to ease lengthy COVID-19 lockdown as vaccination rate rises
Melbourne to ease lengthy COVID-19 lockdown as vaccination rate rises
By Mateen Dalal

The Australian city of Melbourne is reportedly gearing up to lift the world’s longest stay-at-...